Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914186 · ClinicalTrials.gov registry record · Phase 2
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
A Phase 2 study, sponsored by Taisho Pharmaceutical R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00914186: Completed Phase 2 study, sponsored by Taisho Pharmaceutical R&D.
NCT00914186 is a Phase 2 study that has completed, run by Taisho Pharmaceutical R&D. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914186, a Phase 2 study, has completed, sponsored by Taisho Pharmaceutical R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen of twice-daily topical application.
Interventions
- DRUG Vehicle
- DRUG TS022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914186
The ClinicalTrials.gov registry entry for NCT00914186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taisho Pharmaceutical R&D, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT00914186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914186 about?
NCT00914186 is a clinical study titled "Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)". The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen of twice-daily topical application.
What is the current status of trial NCT00914186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2009-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00914186?
The interventions under investigation include: Vehicle (DRUG), TS022 (DRUG).
Who is sponsoring clinical trial NCT00914186?
This trial is sponsored by Taisho Pharmaceutical R&D, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.